Nanoscope to Present Optogenetic Therapy Data in Vienna
The company will disclose clinical results for its macular degeneration and retinitis pigmentosa programs this October.
Updated on Sept. 23, 2026 in Biotech
Nanoscope Therapeutics announced it will present clinical trial data for its optogenetic therapies at the 26th Euretina Congress and Retina Forum 2026. These research-stage presentations will take place in Vienna from September 30 through October 4, 2026.
Why it matters
The upcoming disclosures provide transparency on the performance of experimental vision-restoration treatments. These results are critical for evaluating the long-term potential of optogenetic approaches in managing retinal degenerative diseases.
The presentations will include 4-year extension study data for MCO-010, an optogenetic therapy designed to restore vision in retinitis pigmentosa patients. Researchers will also share randomized controlled trial results for sonpiretigene isteparvovec.
The players
Nanoscope Therapeutics
A biotechnology firm specializing in gene-delivery platforms and optogenetic therapies for retinal diseases.
Jordi Mones
A researcher who will present randomized controlled trial data for the company's optogenetic therapy.
Benjamin Bakall
A clinical investigator who will detail findings from a 4-year extension study on retinal therapies.
Samarendra Mohanty
A company executive tasked with delivering the corporate presentation at the Retina Forum 2026.
Samuel Barone
A medical professional who will discuss clinical developments in geographic atrophy and intermediate AMD.
The details
Optogenetic therapy involves using light-sensitive proteins to restore visual function to retinal cells that have lost their natural photoreceptors. Sonpiretigene isteparvovec and MCO-010 represent different approaches to this gene-delivery process, aiming to bypass damaged cells to signal the optic nerve. These studies focus on quantifying how these interventions maintain vision-restoration in patients with macular degeneration and retinitis pigmentosa.
Timeline
September 30, 2026: Nanoscope Therapeutics officials will present at the Retina Forum 2026 in Vienna.
October 1-4, 2026: Clinical data will be presented during the 26th Euretina Congress at the VIECON - Vienna Congress & Convention Center.
The Tech Race
This disclosure marks a significant update in the competitive field of vision-restoration gene therapies. It extends the evidence base for the REMAIN clinical trial program, allowing stakeholders to compare Nanoscope's long-term results against other emerging optogenetic interventions.
These clinical findings do not currently impact patient care, as both optogenetic therapies remain in the research and trial stage. Interested clinicians and researchers should monitor the upcoming conference proceedings to track the trajectory of these treatment timelines.
The takeaway
The upcoming presentations in Vienna represent a critical checkpoint for the maturation of optogenetic retinal treatments. Observers should track the 4-year extension study findings to assess the durability of vision gains compared to shorter-term clinical data.
What happens next
The clinical results will be released publicly during the Retina Forum 2026 on September 30, 2026, and the 26th Euretina Congress running from October 1 to October 4, 2026.
Further reading
For broader context on current clinical progress in vision research, visit our Biotech section.
